In an adult with type 2 diabetes taking liraglutide 1.2 mg daily, insulin glargine 20 U basal, an insulin‑to‑carbohydrate ratio of 1 U per 10 g carbohydrate and a medium correction factor, and with overnight glucose readings of 314 mg/dL and 301 mg/dL, how should the basal insulin dose, the insulin‑to‑carbohydrate ratio, and the correction factor be adjusted?

Aggressive Insulin Intensification Required for Severe Overnight Hyperglycemia

Immediately increase Lantus by 4 units every 3 days until fasting glucose reaches 80–130 mg/dL, tighten the insulin‑to‑carbohydrate ratio from 1:10 to 1:8, and reduce the correction factor from "medium" to a more aggressive scale (2 units for glucose >250 mg/dL, 4 units for >350 mg/dL) to address the profound under‑dosing evident in overnight readings of 314 and 301 mg/dL. 1

Basal Insulin (Lantus) Titration

• Increase Lantus by 4 units every 3 days when fasting glucose remains ≥180 mg/dL (as in this case with overnight values of 301–314 mg/dL), targeting a fasting range of 80–130 mg/dL. 1
• The current 20‑unit dose is profoundly inadequate; for an adult with severe hyperglycemia, weight‑based dosing of 0.3–0.5 units/kg/day is recommended, meaning a typical adult may require 30–50 units or more as total daily insulin. 1
• Stop basal escalation only when the dose approaches 0.5 units/kg/day (approximately 35–50 units for most adults) without achieving fasting targets; at that threshold, add or intensify prandial insulin rather than continuing basal increases. 1
• Clinical signals of "over‑basalization" include basal dose >0.5 units/kg/day, bedtime‑to‑morning glucose differential ≥50 mg/dL, hypoglycemia episodes, or high glucose variability—none of which apply here given the severe hyperglycemia. 1

Insulin‑to‑Carbohydrate Ratio (ICR) Adjustment

• Tighten the ICR from 1 unit per 10 g carbohydrate to 1 unit per 8 g carbohydrate to provide more aggressive mealtime coverage. 1
• The formula for rapid‑acting insulin ICR is 450 ÷ total daily insulin dose; if total daily insulin is currently ~30 units (20 basal + ~10 prandial), the calculated ICR is 450 ÷ 30 = 15 g per unit, but clinical hyperglycemia warrants a more aggressive ratio. 1
• Reassess the ICR every 3 days based on 2‑hour post‑prandial glucose readings; if post‑prandial glucose consistently exceeds 180 mg/dL, further tighten the ratio to 1:6 or 1:7. 1
• Administer prandial insulin 0–15 minutes before meals for optimal post‑prandial control. 1

Correction Factor (Insulin Sensitivity Factor) Adjustment

• Replace the "medium" correction scale with a simplified aggressive protocol: add 2 units of rapid‑acting insulin for pre‑meal glucose >250 mg/dL and 4 units for glucose >350 mg/dL, in addition to the scheduled prandial dose. 1
• For individualized correction, calculate the insulin sensitivity factor (ISF) as 1500 ÷ total daily insulin dose; if total daily insulin is 30 units, ISF = 1500 ÷ 30 = 50 mg/dL per unit, meaning each unit lowers glucose by ~50 mg/dL. 1
• Correction dose = (Current glucose – Target glucose) ÷ ISF; for example, if pre‑meal glucose is 300 mg/dL and target is 120 mg/dL, correction = (300 – 120) ÷ 50 = 3.6 units, rounded to 4 units. 1
• Correction insulin must supplement—not replace—scheduled basal and prandial insulin; relying solely on correction doses is condemned by major diabetes guidelines. 1

Monitoring and Titration Schedule

• Check fasting glucose daily to guide Lantus adjustments; increase by 4 units every 3 days until fasting glucose consistently reaches 80–130 mg/dL. 1
• Measure pre‑meal glucose before each meal to calculate correction doses. 1
• Obtain 2‑hour post‑prandial glucose after each meal to assess ICR adequacy and guide further tightening. 1
• Reassess insulin doses every 3 days during active titration; do not delay adjustments when glucose remains >180 mg/dL. 1
• Check HbA1c every 3 months until stable control is achieved. 1

Role of Liraglutide (Victoza) 1.2 mg

• Continue liraglutide at 1.2 mg daily as it provides complementary glucose‑lowering effects, improves β‑cell function, promotes weight loss, and reduces hypoglycemia risk when combined with insulin. 2, 3, 4
• Liraglutide typically reduces total insulin requirements by 20–30 % over 8–12 weeks, but immediate aggressive insulin titration is still required given the severity of hyperglycemia. 5
• Do not delay insulin intensification while waiting for liraglutide's full effect to develop; the drug's glucose‑lowering benefit builds over 4–5 weeks. 5
• If basal insulin exceeds 0.5 units/kg/day without achieving targets, consider increasing liraglutide to 1.8 mg daily (if tolerated) as an alternative to further prandial insulin escalation. 2, 3, 4

Expected Clinical Outcomes

• With aggressive basal‑bolus titration, approximately 68 % of patients achieve mean glucose <140 mg/dL, compared with only 38 % using inadequate regimens. 1
• HbA1c reduction of 2–3 % (or 3–4 % in severe hyperglycemia) is achievable within 3–6 months of intensive insulin titration. 1
• Properly implemented basal‑bolus therapy does not increase hypoglycemia incidence relative to under‑dosed insulin. 1
• Liraglutide in combination with insulin provides greater HbA1c reductions, weight loss, and lower hypoglycemia rates compared with insulin intensification alone. 6, 7

Hypoglycemia Management

• Treat any glucose <70 mg/dL immediately with 15 g of fast‑acting carbohydrate, recheck in 15 minutes, and repeat if needed. 1
• If hypoglycemia occurs without an obvious cause, reduce the implicated insulin dose by 10–20 % before the next administration. 1
• Never administer rapid‑acting insulin at bedtime as a sole correction dose, as this markedly raises nocturnal hypoglycemia risk. 1

Critical Pitfalls to Avoid

• Do not delay basal insulin escalation when fasting glucose consistently exceeds 180 mg/dL; prolonged hyperglycemia increases complication risk. 1
• Do not rely solely on correction insulin without adjusting scheduled basal and prandial doses; this reactive approach is condemned by major diabetes guidelines. 1
• Avoid continuing basal insulin escalation beyond 0.5–1.0 units/kg/day without addressing post‑prandial hyperglycemia, to prevent over‑basalization and hypoglycemia. 1
• Do not discontinue or reduce liraglutide during insulin intensification; the combination provides superior outcomes compared with insulin alone. 6, 7